Keryx Biopharmaceuticals (NASDAQ:KERX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.


Player Avatar zzlangerhans (99.85) Submitted: 9/6/2011 5:16:56 PM : Outperform Start Price: $3.79 KERX Score: +9.64

Keryx is another biotech which has struggled recently despite an absence of negative developments specific to the company. The company has already reported positive phase III efficacy data for kidney failure drug Zerenex and is only awaiting results of a phase III safety trial in June 2012 before proceeding with an NDA. Meanwhile, phase III efficacy data for anti-neoplastic agent perifosine in colorectal cancer may be available as early as Q4 2011, although I suspect that timeframe may be pushed back. The trial recently passed the final interim futility analysis. Like all speculative stocks, Keryx could potentially drop much further in a broad decline but is definitely one to watch for a rebound.

Report this Post 2 Replies
Member Avatar BlackSwanCapital (64.76) Submitted: 9/6/2011 6:04:42 PM
Recs: 0

Just trying to get your attention, I replied to your blog post -

Member Avatar Geo73 (< 20) Submitted: 11/30/2011 10:43:18 AM
Recs: 0

I have been looking into this stock for 3 years. I really think that KERX is a good investment going long with it. KERX has the potential of going up to $15.00 or $20.00 if one of those medication are approved by FDA. It may take 2 or 3 years, but I think it will pay off. I will start buying it again when KERX trade at $2.00 because I believe it could go that low. What do you thing?

Featured Broker Partners